allergic rhinitis
Conditions
Interventions
"Biyan Tong" fumigation lotion group:"Biyan Tong" fumigation lotion
Sponsors
Shenzhen Hospital, Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1)Patients voluntarily signed informed consent and could be followed up on schedule; 2)Patients promise to abide by the research procedures and cooperate with the implementation of the whole process of research and late follow-up.(one course of treatment is seven days, twice a day, and one or more courses of treatment are given according to the improvement of the condition); 3)The patients ranged in age from 18 to 55 years old and were of any gender; 4) Meet the classification standard of persistent allergic rhinitis: sneezing, watery nasal discharge, nasal congestion, nasal itching and other symptoms appear more than two (including two), and the symptoms last or accumulate for more than one hour every day. May be accompanied by Itchy eyes, conjunctival congestion and other eye symptoms. The time of the above symptoms =4 days/week, and = 4 consecutive weeks; 5) If it is a male or female in the reproductive period, the patient must take effective contraceptive measures during the study; 6) No other treatment schemes for allergic rhinitis (including corticosteroids, antihistamines, mast cell stabilizers, anticholinergic drugs, immunotherapy (desensitization therapy) have been used in the last 2 weeks, and the investigator believes that the participants are suitable for treatment;
Exclusion criteria
Exclusion criteria: 1) Patients with history of allergy to prescription drugs and their main components, such as scopolamine and atropine; 2) Patients complicated with severe respiratory diseases or asthma; 3) Complicated with serious, progressive or uncontrolled important organs and systemic diseases (including heart diseases, liver and kidney diseases, disease of endocrine, circulatory system, nervous system, etc.) or other autoimmune diseases, malignant tumors and infection history; 4) Patients with increased intraocular pressure and glaucoma; 5) Special population (pregnant and lactating women, patients with severe mental illness, critically ill or terminally ill patients); 6) Participating in other clinical trials at the same time or finishing in less than 30 days; 7)Patients with severe lung diseases, such as COPD (chronic obstructive pulmonary disease); 8) Other circumstances that the investigator thinks are not suitable to participate in the experiment do not belong to the scope of this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TNSS;VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| RQLQ;total IgE;Symptom-drug score; | — |
Countries
China
Contacts
Public ContactWu Fenfang
Shenzhen Hospital, Beijing University of Chinese Medicine
Outcome results
None listed